Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by MasterAlgaeon Oct 28, 2020 12:22pm

248 Views

Post# 31795945

Sell-off again....

ATE is not meaningfully impacted by what the TSX or DOW, S&P etc are doing. It is way too small. If anything it has a negative BETA which means ATE moves in the opposite direction of the markets, (proof that it is disconnected). The BETA of Antibe is "inversely correlated to the market benchmark."

It is tax loss selling season, indeed there has been massive selling in ATE since June - obviously.

Given the lack of news from the company and the wider economic environment, individuals' concerns may be rising about ATE, (I know mine are).

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?